AstraZeneca Annual Report and Cross Reference to Form 20-F Form 20-F Information 2004 Cross Reference to Form 20-F The information in this document that is referenced on this page is included in AstraZenecas Form 20-F for 2004 2004 Form 20-F and is filed with the Securities and Exchange Commission SEC.
The 2004 Form 20-F is the only document intended to be incorporated by reference into any filings by AstraZeneca under the Securities Act of 1933, as amended.
References to major headings include all information under such major headings, including subheadings.
References to subheadings include only the information contained under such subheadings.
Graphs are not included unless specifically identified.
The 2004 Form 20-F has not been approved or disapproved by the SEC nor has the SEC passed comment upon the accuracy or adequacy of the 2004 Form 20-F.
The 2004 Form 20-F filed with the SEC may contain modified information and may be updated from time to time.
Item Page Item Page 3 Key Information 9 The Offer and Listing A.
Price history of listed stock Financial Highlights 7 Shareholder Information 148 Group Financial Record 136 C. Markets Shareholder Information 147 Shareholder Information 148 D. Risk factors 155 10 Additional Information 4 Information on the Company B.
Memorandum and Articles of Association 160 A.
History and development of the Company 160 C. Material contracts n a Financial Review Investments, divestments D. Exchange controls and other limitations and capital expenditure 40 affecting security holders 152 Note 9 Tangible fixed assets 87 E. Taxation 151 Note 24 Disposal of business operations 97 H. Documents on display 151 B.
Subsidiary information Operational Review 11 Principal Subsidiaries 124 C. Organisational structure Directors Report 52 11 Quantitative and Qualitative Disclosures Principal Subsidiaries 124 about Market Risk D. Property, plants and equipment Financial Policies Treasury 42 Operational Review Main Facilities 33 12 Description of Securities other than 5 Operating and Financial Review and Prospects Equity Securities n a A-F.
Operational Review 11 A-F. Financial Review 37 13 Defaults, Dividend Arrearages and Delinquencies n a Note 18 Financial instruments 91 14 Material Modifications to the Rights of Security 6Directors, Senior Management and Employees Holders and Use of Proceeds n a A.
Directors and senior management Board of Directors 8 B.
Compensation 15 Controls and Procedures Directors Remuneration Report 60 Directors Report Internal Controls and Note 28 Post-retirement benefits 99 Management of Risk 54 C. Board practices Board of Directors 8 16 [Reserved] Directors Remuneration Report 60 Directors Report 52 A.
Audit committee financial expert Audit Committees Report 58 Audit Committees Report 58 D. Employees B.
Code of ethics Note 29 Employee costs and share option Directors Report Code of Conduct 55 plans for employees 104 C. Principal accountant fees and services Directors Report Employees 56 Note 32 Statutory and other information 119 E. Share ownership D. Exemptions from the listing standards Directors Remuneration Report for audit committees n a Directors Interests in Shares 67 E. Purchases of equity securities by the issuer Note 29 Employee costs and and affiliated purchasers share option plans for employees 104 Note 34 Called-up share capital of parent company 123 7 Major Shareholders and Related Party Transactions 18 Financial Statements A.
Major shareholders Shareholder Information Major shareholdings 149 Financial Statements excluding Directors B.
Related party transactions responsibilities on page 70 and Auditors Shareholder Information Related party opinion on page 71 72 transactions 150 Note 32 Statutory and other information 119 8 Financial Information A.
Consolidated statements and other financial information Financial Statements excluding Directors responsibilities on page 70 and Auditors opinion on page 71 72 B.
